Literature DB >> 11372066

Surgery for ischemic pain and Raynaud's' phenomenon in scleroderma: a description of treatment protocol and evaluation of results.

M M Tomaino1, R J Goitz, T A Medsger.   

Abstract

Although the literature suggests that palmar sympathectomy (PS) with or without vascular reconstruction may improve ischemic digital pain, fingertip ulceration, and cold intolerance in patients with scleroderma, the question regarding long-term efficacy still remains. This retrospective study of six patients (eight hands) operated on between 1995 and 1997 evaluates both early (6 months) and long-term (average, 2.5 years) outcome after PS in combination with decompression arteriolysis of the radial and ulnar arteries proximal to the wrist. When preoperative digital blood flow was inadequate based on noninvasive vascular studies and major inflow occlusion was present, vascular reconstruction was also performed when feasible. At early review, significant improvement in ischemic digital pain and moderate improvement in cold intolerance resulted in eight hands, and at final follow-up, this was sustained in seven hands. Preoperatively, digital ulcerations were present in six hands. After digital debridement and/or amputation, all wounds healed, but in one patient with bilateral disease who continued to smoke, ulcerations recurred without the need for subsequent surgery. Five of six patients were no longer dependent on narcotic analgesics, but use of vasodilator medication did not change. Five of six patients claimed significant improvement in the quality of life after surgery and reported that they would undergo the surgery again. PS in combination with radial and ulnar arteriolysis appears to be efficacious at both early and long-term review. When major inflow occlusion exists and digital blood flow is compromised, vascular reconstruction is recommended if possible. We review our treatment protocol in this complex population of patients. Copyright 2001 Wiley-Liss, Inc. Microsurgery 21:75-79 2001

Entities:  

Mesh:

Year:  2001        PMID: 11372066     DOI: 10.1002/micr.1013

Source DB:  PubMed          Journal:  Microsurgery        ISSN: 0738-1085            Impact factor:   2.425


  9 in total

Review 1.  The pathogenesis, diagnosis and treatment of Raynaud phenomenon.

Authors:  Ariane L Herrick
Journal:  Nat Rev Rheumatol       Date:  2012-07-10       Impact factor: 20.543

2.  Raynaud's phenomenon.

Authors:  Ariane Herrick
Journal:  Curr Treat Options Cardiovasc Med       Date:  2008-04

3.  Intermediate-term follow-up of chronically ill patients with digital ischemia treated with peripheral digital sympathectomy.

Authors:  José R Soberón; Roy A Greengrass; William E Davis; Peter M Murray; Neil Feinglass
Journal:  Rheumatol Int       Date:  2016-02       Impact factor: 2.631

4.  Current Treatment Options in Raynaud's Phenomenon.

Authors:  Sergio Generini; Angela Del Rosso; Alberto Pignone; Marco Matucci Cerinic
Journal:  Curr Treat Options Cardiovasc Med       Date:  2003-04

Review 5.  Old medications and new targeted therapies in systemic sclerosis.

Authors:  Vivek Nagaraja; Christopher P Denton; Dinesh Khanna
Journal:  Rheumatology (Oxford)       Date:  2014-07-26       Impact factor: 7.580

6.  Sonographically guided hydrodissection and corticosteroid injection for scleroderma hand.

Authors:  Suzanne L DeLea; Natalia R Chavez-Chiang; Janet L Poole; Hillary E Norton; Wilmer L Sibbitt; Arthur D Bankhurst
Journal:  Clin Rheumatol       Date:  2011-01-15       Impact factor: 2.980

7.  Management of Raynaud's Phenomenon in the Patient with Connective Tissue Disease.

Authors:  Soumya Chatterjee
Journal:  Curr Treat Options Cardiovasc Med       Date:  2010-04

8.  Treatment of Raynaud's phenomenon: new insights and developments.

Authors:  Ariane L Herrick
Journal:  Curr Rheumatol Rep       Date:  2003-04       Impact factor: 4.686

9.  Locoregional Treatments for Digital Ulcers in Systemic Sclerosis: A Systematic Review.

Authors:  Ingrid Costedoat; Maeva Masson; Thomas Barnetche; Pierre Duffau; Estibaliz Lazaro; Christophe Richez; Julien Seneschal; Marie-Elise Truchetet
Journal:  Acta Derm Venereol       Date:  2021-06-22       Impact factor: 3.875

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.